Effects of idecabtagene vicleucel (ide-cel) versus standard regimens on health-related quality of life (HRQoL) in patients with triple-class-exposed (TCE) relapsed/refractory multiple myeloma (RRMM) who received at least 3 lines of prior antimyeloma regimens in the KarMMa-3 phase 3 randomized controlled trial Meeting Abstract
| Authors: | Delforge, M.; Patel, K. K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T. S.; Arnulf, B.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N. S.; Giralt, S. A.; Einsele, H.; Ailawadhi, S.; Popa-McKiver, M.; Cook, M.; Otero, P. R. |
| Abstract Title: | Effects of idecabtagene vicleucel (ide-cel) versus standard regimens on health-related quality of life (HRQoL) in patients with triple-class-exposed (TCE) relapsed/refractory multiple myeloma (RRMM) who received at least 3 lines of prior antimyeloma regimens in the KarMMa-3 phase 3 randomized controlled trial |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 1003 |
| Language: | English |
| ACCESSION: | WOS:001159306704027 |
| DOI: | 10.1182/blood-2023-173849 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
